Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis

Recruitment & Eligibility

Inclusion Criteria

Male or female aged ≥20years
Signed and dated informed consent document indicating that the patient
Women of childbearing potential must have a negative serum or urine pregnancy test at the screening visit. Except in the case of surgically sterile or amenorrhea for one year.
Female patients must agree to use adequate contraception measures during the period of therapy which should be continued for 4 weeks.
have RA and meet all of the following criteria; RA occurring ≥ 3months and less than 15 years and diagnosed based on 1987 ACR classification criteria for rheumatoid arthritis; Active RA patients with MTX and among them who has insufficiency response to DMARDs as defined DAS28>3.2 in active RA patient. Insufficiency response is defined despite MTX therapy for > 12 weeks, RA activity≥ more than moderate and confirmable during 12 weeks, sequence of taking MTX >7.5mg/week for more than 6 weeks; ESR≥28mm/h or CRP≥1.0mg/dl; Tender Joint Counts must be more than 6 and Swollen Joint Counts must be more than 3

Exclusion Criteria

Inflammatory joint diseases, Systematic inflammatory disease
Prosthesis and had an event of infected in it.
Medical history of chronic infection, moderate infection or possibly to life threatening or signs and symptoms of serious infection.
Patients have received treatment with a live vaccine from baseline within 8 weeks.
HBsAg positive and hepatitis C virus positive patient.
Patients have a history of malignancy. (But, carcinoma in situ of the uterine cervix or basal cell carcinoma have been treated is allowed within 5years)
Patients have cardiovascular disease or associated disease which is not controlled.
uncontrollable blood sugar(HbA1C ≥8%) or required insulin.
Patients with a history of operation on index knee joint which could have influence on the result and need to have surgery as determined by investigator.
At screening, patients have laboratory result as defined by ; white blood cell(WBC) < 3,500/mm3, Absolute Neutrophil Count(ANC) < 1,500/mm3, Hemoglobin < 8.5g/dl, Platelet count(PLT) < 100,000/mm3, Serum creatinine >1.5*upper limit of normal or 2mg/dl, Total bilirubin > 2*upper limit of normal, aspartate aminotransferase(AST) > 2*upper limit of normal, alanine aminotransferase(ALT) > 2*upper limit of normal, alkaline phosphatase(ALP) > 2*upper limit of normal
Patients on any other clinical trial or experimental treatment in the past 8weeks
An impossible one who participates in clinical trial by investigator's decision

Study & Design

Arm && Interventions

Group	Intervention	Description
Tacrolimus with Methotrexate	Tacrolimus with Methotrexate	Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0\~4 weeks, 2mg for 4 weeks\~8 weeks, 3mg for 8 weeks\~24 weeks

Primary Outcome Measures

Name	Time	Method
Change from baseline European League Against Rheumatism(EULAR) response at 24weeks	baseline, 24weeks

Secondary Outcome Measures

Name	Time	Method
Change from baseline Simplified Disease Activity Index(SDAI) at 24weeks	baseline, 24weeks
Change from baseline C-Reactive Protein(CRP) at 24weeks	baseline, 24weeks
Change from baseline Korean Health Assessment Questionnaire(KHAQ-20) at 24weeks	baseline, 24weeks
Change from baseline Erythrocyte Sedimentation Rate(ESR) at 16weeks	baseline, 16weeks
Change from baseline Erythrocyte Sedimentation Rate(ESR) at 24weeks	baseline, 24eeks
Change from baseline C-Reactive Protein(CRP) at 16weeks	baseline, 16weeks
Change from baseline European League Against Rheumatism(EULAR) response at 16weeks	baseline, 16weeks

Recruitment & Eligibility